Treatment of intragraft stenosis in hemodialysis grafts with Supera stents: A retrospective study.

Pub Date : 2024-01-01 Epub Date: 2022-05-30 DOI:10.1177/11297298221077605
Chai-Hock Chua, Ming-Jen Lu, Hung-Hsing Chao
{"title":"Treatment of intragraft stenosis in hemodialysis grafts with Supera stents: A retrospective study.","authors":"Chai-Hock Chua, Ming-Jen Lu, Hung-Hsing Chao","doi":"10.1177/11297298221077605","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To report the patency rates after implantation of an interwoven nitinol stent to salvage failing arteriovenous grafts (AVGs) caused by intragraft stenoses.</p><p><strong>Methods: </strong>Between May 2018 and May 2020, 21 Supera stents were placed in 20 patients (18 women; mean age: 79.9 years) who had a failing AVG due to repeat intragraft stenoses. Recurrent AVG dysfunction with same intragraft stenosis within 3 months after first time angioplasty was a criterion for stenting. Those with concurrent treatment for other lesions were excluded.</p><p><strong>Results: </strong>The technical success rate was 100%. Intragraft stenoses were treated at a median of 19.7 (interquartile range: 6-36) months after graft creation. Access circuit primary patency rates after stent placement were 84% and 35% at 6 and 12 months, respectively. Access circuit secondary patency rates were 100% at 6 and 12 months and 89% at 18 months. Only one patient presented with graft failure due to proximal drainage vein occlusion. The target lesion patency rates were 100% at 6 months and 75% at 12 months. The rate of reintervention for intragraft lesion was 0.15 procedures per year. Stent distortion did not occur under regular cannulation.</p><p><strong>Conclusion: </strong>The interwoven nitinol stent is a promising treatment for failing AVGs with recurrent intragraft stenoses. The 1-year access circuit primary, secondary, and target lesion patency rates were acceptable, with a low reintervention rate. Stent fracture does not occur in areas of needle puncture.</p>","PeriodicalId":92951,"journal":{"name":"","volume":"24 1","pages":"125-131"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11297298221077605","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/5/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To report the patency rates after implantation of an interwoven nitinol stent to salvage failing arteriovenous grafts (AVGs) caused by intragraft stenoses.

Methods: Between May 2018 and May 2020, 21 Supera stents were placed in 20 patients (18 women; mean age: 79.9 years) who had a failing AVG due to repeat intragraft stenoses. Recurrent AVG dysfunction with same intragraft stenosis within 3 months after first time angioplasty was a criterion for stenting. Those with concurrent treatment for other lesions were excluded.

Results: The technical success rate was 100%. Intragraft stenoses were treated at a median of 19.7 (interquartile range: 6-36) months after graft creation. Access circuit primary patency rates after stent placement were 84% and 35% at 6 and 12 months, respectively. Access circuit secondary patency rates were 100% at 6 and 12 months and 89% at 18 months. Only one patient presented with graft failure due to proximal drainage vein occlusion. The target lesion patency rates were 100% at 6 months and 75% at 12 months. The rate of reintervention for intragraft lesion was 0.15 procedures per year. Stent distortion did not occur under regular cannulation.

Conclusion: The interwoven nitinol stent is a promising treatment for failing AVGs with recurrent intragraft stenoses. The 1-year access circuit primary, secondary, and target lesion patency rates were acceptable, with a low reintervention rate. Stent fracture does not occur in areas of needle puncture.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用 Supera 支架治疗血液透析移植物内部狭窄:回顾性研究。
目的:报告植入交织镍钛诺支架后的通畅率,以挽救因移植物内狭窄导致的衰竭动静脉移植物(AVG):在2018年5月至2020年5月期间,为20名因移植物内重复狭窄导致动静脉移植物功能衰竭的患者(18名女性;平均年龄:79.9岁)植入了21枚Supera支架。首次血管成形术后 3 个月内再次出现动静脉瓣功能障碍并伴有相同的移植血管内狭窄是支架植入的标准。那些同时接受其他病变治疗的患者被排除在外:结果:技术成功率为 100%。移植物内狭窄的治疗时间中位数为移植物创建后19.7个月(四分位间范围:6-36个月)。支架置入后 6 个月和 12 个月的通路一次通畅率分别为 84% 和 35%。6个月和12个月时,通路二次通畅率为100%,18个月时为89%。只有一名患者因近端引流静脉闭塞而导致移植失败。6 个月和 12 个月的靶病变通畅率分别为 100%和 75%。因移植物内病变而再次介入的比例为每年0.15次。在常规插管情况下,支架未发生变形:结论:交织镍钛诺支架是一种很有前途的治疗方法,可用于治疗复发性血管内狭窄的失败动静脉导管。1年通路原发性、继发性和靶病变通畅率均可接受,再介入率较低。支架断裂不会发生在针刺部位。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1